CClinicalTrials.gg
Sign In
CompletedNCT02020577Updated Jun 22, 2017Results posted

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

A Phase 1 interventional study of Cetuximab( erbitux®) and Afatinib in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The trial is divided in two parts, Part A and Part B. Part A will involve dose-finding of dose-limiting toxicity (DLT) and MTD in patients with advanced solid tumours. Part B will involve expansion of the MTD to 3 cohorts including non-small cell lung cancer squamous histology, recurrent/ metastatic squamous cell carcinoma of head and neck and other advanced solid tumours (except sarcomas).

02

Conditions studied

  • Neoplasms
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Part A only

  1. Patients must have advanced malignant solid tumours that are metastatic or unresectable
  2. At least one measurable or evaluable (non-measurable) lesion per RECIST 1.1 Part B only

  3. Patients must have:

    1. measurable disease per RECIST 1.1

    2. diagnosis of one of the following

      • Advanced Non-Small Cell Lung Cancer -Squamous Histology (NSCLC-SQ) with no more than 2 lines of chemotherapy for advanced/metastatic disease ( prior EGFR directed treatment is permitted) or
      • Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) no more than 2 lines of chemotherapy for advanced disease and no more than 1 line of prior cetuximab permitted.

    or

    • Other malignant solid tumours except sarcomas (for metastatic colorectal cancer, only wild type KRAS are permitted) Part A and B
  4. Age 18 years or older
  5. Written informed consent that is consistent with ICH-GCP guidelines and local law.
  6. Histological/Cytological confirmed diagnosis of malignant solid tumours (exclusion of sarcomas)
  7. Advanced disease for whom standard treatment is ineffective or no longer effective
  8. Recovered from previous therapy related AE to \</= Grade 1 at the study entry (except, for stable sensory neuropathy \</= Grade 2 and alopecia)
  9. Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.

  10. Adequate organ function as defined by the following criteria:

    • LVEF >50% or within institutional values
    • Absolute neutrophil count (ANC) >1500/ mm3
    • Platelet count >75.000/ mm3
    • Estimated creatinine clearance > 45ml/ min
    • Total bilirubin\<1.5 times upper limit of institutional normal
    • Aspartate amino transferase (AST) or alanine amino transferase (ALT) \<3 x upper limit of institutional normal (ULN) (if related to liver metastases\< 5xULN)

Exclusion criteria

Exclusion criteria:

  1. Chemotherapy, biological therapy or investigational agents within 4 weeks prior to the start of study treatment.
  2. Hormonal anti-cancer treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues [LHRH] is permitted)

  3. Radiotherapy within 4 weeks prior to the start of study treatment, except as follows:

    1. Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, and
    2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
  4. Major surgery (as judged by the investigator) within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
  5. Known hypersensitivity to afatinib or the excipients of any of the trial drugs
  6. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior start treatment.

  7. Female patients of childbearing potential who:

    1. are nursing or
    2. are pregnant or
    3. are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
  8. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
  9. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.
  10. Requiring treatment with any of the prohibited concomitant medications listed in the protocol that can not be stopped for the duration of trial participation
  11. Known pre-existing interstitial lung disease
  12. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption)
  13. Active hepatitis B infection (defined as presence of HepB sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
  14. Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment.
  15. Meningeal carcinomatosis
  16. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment.
  17. Any SPC listed contra-indications for cetuximab
  18. Use of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    combination arm

    Patients to receive afatinib once daily plus weekly cetuximab infusion

    Drug: Cetuximab( erbitux®) · Drug: Afatinib

Interventions

  • DrugCetuximab( erbitux®)

    once per week

  • DrugAfatinib

    once per day

06

What researchers measure

Primary outcomes

  1. MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).

    Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with dose limiting toxicity (DLT) during the first treatment cycle (Dose escalation part). The MTD is defined as the highest dose level at which less than 33% of the patients experience DLT in first treatment cycle.

    Time frame: First 21 days treatment cycle

  2. Dose Limiting Toxicities During Cycle 1

    Number of Patients With Dose Limiting Toxicity (DLT) Occurring during Cycle 1. The following drug related AEs qualified as DLT: 1) CTCAE Grade ≥2 decrease in cardiac left ventricular function 2) CTCAE Grade 2 diarrhoea lasting for ≥7 days, despite appropriate use of standard antidiarrheal therapy based on Protocol Amendment 1 dated 22 Oct 2013 3) CTCAE Grade ≥3 diarrhoea despite appropriate use of standard anti-diarrheal therapy for at least 2 days. 4) CTCAE Grade ≥3 nausea and/or vomiting despite appropriate use of standard anti-emetics for at least 3 days 5) CTCAE Grade ≥3 rash despite standard medical management. 6) CTCAE Grade ≥3 fatigue lasting more than 7 days. 7) All other AEs of CTCAE Grade ≥3 (except alopecia and allergic reaction) that led to an interruption of afatinib and/or cetuximab dosing for more than 14 days until recovery to baseline or Grade 1, whichever was higher. 8) CTCAE Grade 4 hypomagnesemia or Grade 3 hypomagnesemia with clinically-significant sequelae

    Time frame: First 21-day treatment cycle

  3. MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).

    Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with DLTs during the first treatment cycle (Dose escalation part).

    Time frame: First treatment cycle

Secondary outcomes

  1. Dose Limiting Toxicities During All Treatment Cycles

    Number of patients with DLT occuring during all treatment cycle is presented

    Time frame: All treatment cycle (each treatment cycle of 21 days)

  2. Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)

    MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

    Time frame: All treatment cycle (each treatment cycle of 21 days)

  3. Best Overall Response

    Best overall response (according to RECIST version 1.1) was defined as the best response recorded at any time from the first administration of afatinib or cetuximab to the End of Treatment (EOT). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

    Time frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months

  4. Objective Response

    Objective response was defined as the proportion of patients with measurable disease having at least a best overall response of complete response (CR) or partial response (PR), according to RECIST version 1.1. As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

    Time frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months

  5. Disease Control Rate

    For patients with measurable disease, disease control was defined as the proportion of patients having at least a best overall response of CR, PR or stable disease (SD). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression

    Time frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months

  6. Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)

    MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

    Time frame: All treatment cycle (each treatment cycle of 21 days)

07

Results

Posted Feb 12, 2016

Participant flow

Participant flow — Overall Study
MilestoneAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Started355
Completed00
Not completed355
Withdrew: Progressive disease338
Withdrew: Other ae or clinical progression015
Withdrew: Withdrawal by subject01
Withdrew: Other than stated above01

Outcome measures

PrimaryMTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).

Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with dose limiting toxicity (DLT) during the first treatment cycle (Dose escalation part). The MTD is defined as the highest dose level at which less than 33% of the patients experience DLT in first treatment cycle.

Time frame:
First 21 days treatment cycle
Reported as:
Number · mg
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).
mgAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).NA40
PrimaryDose Limiting Toxicities During Cycle 1

Number of Patients With Dose Limiting Toxicity (DLT) Occurring during Cycle 1. The following drug related AEs qualified as DLT: 1) CTCAE Grade ≥2 decrease in cardiac left ventricular function 2) CTCAE Grade 2 diarrhoea lasting for ≥7 days, despite appropriate use of standard antidiarrheal therapy based on Protocol Amendment 1 dated 22 Oct 2013 3) CTCAE Grade ≥3 diarrhoea despite appropriate use of standard anti-diarrheal therapy for at least 2 days. 4) CTCAE Grade ≥3 nausea and/or vomiting despite appropriate use of standard anti-emetics for at least 3 days 5) CTCAE Grade ≥3 rash despite standard medical management. 6) CTCAE Grade ≥3 fatigue lasting more than 7 days. 7) All other AEs of CTCAE Grade ≥3 (except alopecia and allergic reaction) that led to an interruption of afatinib and/or cetuximab dosing for more than 14 days until recovery to baseline or Grade 1, whichever was higher. 8) CTCAE Grade 4 hypomagnesemia or Grade 3 hypomagnesemia with clinically-significant sequelae

Time frame:
First 21-day treatment cycle
Reported as:
Number · Participants
Dose Limiting Toxicities During Cycle 1
ParticipantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Dose Limiting Toxicities During Cycle 100
PrimaryMTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).

Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with DLTs during the first treatment cycle (Dose escalation part).

Time frame:
First treatment cycle
Reported as:
Number · mg/m2
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).
mg/m2Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).NA250
SecondaryDose Limiting Toxicities During All Treatment Cycles

Number of patients with DLT occuring during all treatment cycle is presented

Time frame:
All treatment cycle (each treatment cycle of 21 days)
Reported as:
Number · Participants
Dose Limiting Toxicities During All Treatment Cycles
ParticipantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Dose Limiting Toxicities During All Treatment Cycles099
SecondaryRecommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)

MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

Time frame:
All treatment cycle (each treatment cycle of 21 days)
Reported as:
Number · mg/m2
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)
mg/m2Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)NA250
SecondaryBest Overall Response

Best overall response (according to RECIST version 1.1) was defined as the best response recorded at any time from the first administration of afatinib or cetuximab to the End of Treatment (EOT). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

Time frame:
Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months
Reported as:
Number · Percentage of participants
Best Overall Response
Percentage of participantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Complete Response (CR)0.00.00.0
Partial Response (PR)0.00.00.0
Stable Disease (SD)66.752.753.4
Progressive disease (PD)33.334.534.5
Not evaluable (NE)/Missing0.012.712.1
SecondaryObjective Response

Objective response was defined as the proportion of patients with measurable disease having at least a best overall response of complete response (CR) or partial response (PR), according to RECIST version 1.1. As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

Time frame:
Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months
Reported as:
Number · Percentage of participants
Objective Response
Percentage of participantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Objective Response0.00.00.0
SecondaryDisease Control Rate

For patients with measurable disease, disease control was defined as the proportion of patients having at least a best overall response of CR, PR or stable disease (SD). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression

Time frame:
Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months
Reported as:
Number · Percentage of participants
Disease Control Rate
Percentage of participantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Disease Control Rate66.752.753.4
SecondaryRecommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)

MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

Time frame:
All treatment cycle (each treatment cycle of 21 days)
Reported as:
Number · mg
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)
mgAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)NA40

Adverse events

Collected over From first drug administration until 28 days after last drug administration, up to 19 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Afatinib 30mg+Cetuximab 250 mg/m²—1/3 (33.3%)3/3 (100%)
Afatinib 40mg+Cetuximab 250 mg/m²—31/55 (56.4%)54/55 (98.2%)
All Patients—32/58 (55.2%)57/58 (98.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Upper limb fractureInjury, poisoning and procedural complications1/30/551/58
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/35/556/58
Cognitive disorderNervous system disorders1/30/551/58
SepsisInfections and infestations0/33/553/58
DehydrationMetabolism and nutrition disorders0/33/553/58
DiarrhoeaGastrointestinal disorders0/32/552/58
AstheniaGeneral disorders0/32/552/58
Respiratory tract infectionInfections and infestations0/32/552/58
HypercalcaemiaMetabolism and nutrition disorders0/32/552/58
HypokalaemiaMetabolism and nutrition disorders0/32/552/58
Most frequent other events
Showing 10 of 55
Most frequent other events
EventAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Dermatitis acneiformSkin and subcutaneous tissue disorders2/322/5524/58
Dry skinSkin and subcutaneous tissue disorders2/314/5516/58
DiarrhoeaGastrointestinal disorders1/335/5536/58
HypomagnesaemiaMetabolism and nutrition disorders0/326/5526/58
ConstipationGastrointestinal disorders1/36/557/58
StomatitisGastrointestinal disorders1/311/5512/58
FatigueGeneral disorders1/311/5512/58
ConjunctivitisInfections and infestations1/35/556/58
ParonychiaInfections and infestations1/317/5518/58
ArthralgiaMusculoskeletal and connective tissue disorders1/30/551/58

Baseline characteristics

Treated set: This patient set includes all patients enrolled in the trial who were documented to have taken at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²Total
Mean63.3 ± 7.661.0 ± 11.461.1 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²Total
Female02020
Male33538
08

Study locations

2 sites
  • 1200.122.33001 Boehringer Ingelheim Investigational Site
    Villejuif Cedex, France
  • 1200.122.34001 Boehringer Ingelheim Investigational Site
    Madrid, Spain
09

References and documents

Publications

  • Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018 Nov;104:1-8. doi: 10.1016/j.ejca.2018.07.011. Epub 2018 Oct 1. Erratum In: Eur J Cancer. 2019 Sep;119:198. doi: 10.1016/j.ejca.2018.12.018. PubMed 30278378 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02020577
Lead sponsor
Boehringer Ingelheim
Responsible party
Sponsor
First posted
Dec 25, 2013
Start date
Dec 2013
Primary completion
Jan 2015
Completion
Apr 2016
Results posted
Feb 12, 2016
Last update
Jun 22, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Boehringer Ingelheim

Start the discussion